The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel disease modifying treatment for Parkinson´s disease with potential to improve the quality of life for the patients. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 697790 to develop biomarkers for Parkinson´s disease.
Parkinson’s disease is one of the most prevalent neurological disorders with a significant unmet medical need. World-wide more than 4.6 million individuals over the age of 50 suffer from Parkinson’s disease and it is estimated that the number will more than double by 2030. Today, only symptomatic therapies are available for Parkinson’s disease and there is a huge unmet medical need for treatments that slow or halt the progression of the disease. Early diagnosis and disease modifying treatment are important for improved patient outcomes. BioArctic Neuroscience is developing a Parkinson’s disease biomarker assay, with the potential of becoming the first biochemical biomarker assay that can reflect the underlying pathophysiology of disease.
In the Parkinson´s disease program, BioArctic has close collaboration with Uppsala University and other Swedish universities in Lund, Linköping, Gothenburg and with Karolinska Institutet.
“We are grateful for the support from EU. The development of a sensitive and specific biomarker that also could mirror the treatment effect would make an enormous advantage in the development of new disease modifying therapeutics”, says Dr. Gunilla Osswald, CEO of BioArctic Neuroscience AB.
For further information, please contact;
BioArctic Neuroscience AB
Gunilla Osswald, CEO
Phone: +46 8 695 69 31